SCHEMBL17149739

SCHEMBL17149739

CC(C)CCC[C@@H](C)[C@H]1CCC2C3CC=C4C[C@@H](OC(=O)CN)CC[C@]4(C)C3CC[C@@]21C

nearest known ligand 0.86

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ POLA1 P09884 1/20 0.75
▸ CYP46A1 Q9Y6A2 2/20 0.73
▸ OSBP P22059 3/20 0.69
▸ USP2 O75604 2/20 0.69
▸ RORC P51449 2/20 0.69
▸ LMNA P02545 1/20 0.69
▸ ABCB1 P08183 1/20 0.69
▸ OSBP2 Q969R2 1/20 0.69
▸ FGF2 P09038 1/20 0.66
▸ NR1H3 Q13133 3/20 0.61
▸ NPC1L1 Q9UHC9 2/20 0.60
▸ NPC1 O15118 1/20 0.60
▸ CYP1A2 P05177 1/20 0.59
▸ PLA2G2A P14555 1/20 0.59
▸ GRIN1 Q05586 1/20 0.59
▸ GRIN2A Q12879 1/20 0.59
▸ GBA1 P04062 2/20 0.58
▸ UGCG Q16739 2/20 0.58
▸ GBA2 Q9HCG7 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12500754 1.00 POLA1 (0.75) POLA1CYP46A1OSBPUSP2RORC
SCHEMBL27321810 1.00 POLA1 (0.75) POLA1CYP46A1OSBPUSP2RORC
SCHEMBL27321641 1.00 POLA1 (0.75) POLA1CYP46A1OSBPUSP2RORC
SCHEMBL27417377 1.00 POLA1 (0.75) POLA1CYP46A1OSBPUSP2RORC
SCHEMBL12500755 1.00 POLA1 (0.75) POLA1CYP46A1OSBPUSP2RORC
SCHEMBL30862601 1.00 POLA1 (0.75) POLA1CYP46A1OSBPUSP2RORC
SCHEMBL30862600 1.00 POLA1 (0.75) POLA1CYP46A1OSBPUSP2RORC
SCHEMBL4370706 1.00 POLA1 (0.75) POLA1CYP46A1OSBPUSP2RORC
SCHEMBL30862603 1.00 POLA1 (0.75) POLA1CYP46A1OSBPUSP2RORC
Trifluoroacetic Acid SCHEMBL8350692 0.94 POLA1 (0.70) POLA1CYP46A1OSBPUSP2RORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10426753-B2 Supramolecular combinatorial therapeutics INVICTUS ONCOLOGY PVT. LTD. (IN) 2019-10-01 — — US disclosed
US-20170112800-A1 SUPRAMOLECULAR COMBINATORIAL THERAPEUTICS INVICTUS ONCOLOGY PVT. LTD. (IN) 2017-04-27 — — US disclosed
US-20170112800-A1 SUPRAMOLECULAR COMBINATORIAL THERAPEUTICS INVICTUS ONCOLOGY PVT. LTD. (IN) 2017-04-27 — — US disclosed
WO-2015153345-A1 SUPRAMOLECULAR COMBINATORIAL THERAPEUTICS INVICTUS ONCOLOGY PVT. LTD. (IN) 2015-10-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170112800-A1 SUPRAMOLECULAR COMBINATORIAL THERAPEUTICS PDCD1LG2, PDCD1, ERBB3 POLA1 3019/4885CYP46A1 2429/4885OSBP 2179/4885
US-10426753-B2 Supramolecular combinatorial therapeutics PDCD1LG2, PDCD1, ERBB3 POLA1 3019/4885CYP46A1 2429/4885OSBP 2179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback